Achieving lipid goals in Europe: how large is the treatment gap?
Despite the established benefits of decreasing low-density lipoprotein cholesterol levels in reducing morbidity and mortality from coronary heart disease, not all patients who would benefit from lipid-lowering therapy are being managed appropriately. An in-depth review of the literature (2000-2003) demonstrates that the 'treatment gap' varies across different clinical settings. Although the use of lipid-lowering agents has increased in recent years, there continues to be a widespread failure in the achievement of recommended lipid levels. A combination of the use of the most efficacious statins, together with intervention strategies to ensure that all eligible individuals receive appropriate treatment to achieve lipid goals, are important considerations in minimizing the burden of dyslipidemia in Europe.
Schwandt
Peter
P
Institute for Arteriosclerosis Prevention, Wilbrechtstr. 95, D-81477 Munich, Germany. API.Schwandt.Haas@t-online.de
Brady
Adrian J B
AJ
D008078:Cholesterol, LDL / Q000187:drug effects / Q000378:metabolism; D003327:Coronary Disease / Q000453:epidemiology / Q000378:metabolism; D005060:Europe / Q000453:epidemiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000453:epidemiology; D000960:Hypolipidemic Agents / Q000592:standards / Q000627:therapeutic use*; D012307:Risk Factors
D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents